# US 2001/0051372 A1 · Human hematopoietic stem and progenitor cell antigen and methods for its use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0051372 A1
- Document ID: US20010051372A1
- Status: Published application
- Kind: A1
- Application number: 09/881,853
- Filed: 2001-06-13
- Published: 2001-12-13
- Earliest claimed: 1996-04-26
- Inventors: Amy H. Yin; Sheri Miraglia; Wayne G. Godfrey; David W. Buck
- Web page: https://patentgrep.com/patent/US20010051372A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- G01N 33/56966: {Animal cells}
- Y10S 530/806: Antigenic peptides or proteins
- Y10S 530/838: Marrow; spleen
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

A hematopoietic progenitor cell antigen and reagents, notably antibodies, that specifically bind to the antigen are provided. Expression of the antigen is highly tissue specific. It is only detected on a subset of hematopoietic progenitor cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. The subset of cells recognized by AC133 is CD34bright and contains substantially all of the CFU-GM activity present in the CD34+ population. This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells. Cells selected for expression of AC133 antigen can be further purified by selection for other hematopoietic stem cell and progenitor cell markers.

## Claims

### Claim 1

An antibody that specifically binds to AC133 antigen.

### Claim 2 (depends on 1)

An antibody according to claim 1, wherein said antibody is a monoclonal antibody produced by a hybridoma cell line.

### Claim 3 (depends on 2)

A monoclonal antibody according to claim 2, wherein said antibody blocks simultaneous binding to said antigen by the antibody produced by the hybridoma cell line ATCC.

### Claim 4 (depends on 1)

A monoclonal antibody according to claim 1, wherein said antibody is induced through contralateral immunization.

### Claim 5 (depends on 1)

A monoclonal antibody according to claim 1, produced by the hybridoma cell line ATCC ______.

### Claim 6

A method for enrichment of hematopoietic stem or progenitor cells or both, said method comprising:
combining a mixed population of human cells comprising hematopoietic stem or progenitor cells or both with a reagent that specifically binds to the hematopoietic progenitor cell antigen recognized by the antibody produced by the hybridoma cell line ATCC ______; and
selecting for those cells that bind said reagent;
wherein said selected cells are enriched in hematopoietic stem or progenitor cell activity or both, depending on whether said mixed popluation of human cells contained hematopoietic stem or progenitor cells or both, respectively.

### Claim 7 (depends on 6)

A method according to claim 6, further comprising:
combining said mixed population of human cells with a reagent that specifically recognize at least one of the cell surface markers CD90, CDll 7 and HLA-DR; and
selecting for those cells that are positive for said at least one of said cell surface markers.

### Claim 8 (depends on 6)

A method according to claim 6, wherein said reagent is an antibody or an antibody mixture.

### Claim 9 (depends on 8)

A method according to claim 8, wherein at least one of said antibodies is fluorochrome conjugated.

### Claim 10 (depends on 9)

A method according to claim 9, wherein said selecting with said fluorochrome conjugated antibodies is by flow cytometry.

### Claim 11 (depends on 8)

A method according to claim 8, wherein at least one of said antibodies is conjugated to magnetic particles.

### Claim 12 (depends on 11)

A method according to claim 11, wherein said selecting with said magnetic particle conjugated antibodies is by high gradient magnetic selection.

### Claim 13

A substantially pure population of hematopoietic progenitor cells, wherein said cells are bound to a reagent that specifically binds to the hematopoietic progenitor cell antigen recognized by the antibody produced by the hybridoma cell line ATCC HB12346.

### Claim 14 (depends on 13)

A substantially pure population of hematopoietic progenitor cells according to claim 13, wherein said reagent is a monoclonal antibody.

### Claim 15 (depends on 14)

A substantially pure population of hematopoietic progenitor cells according to claim 14, wherein said monoclonal antibody is produced by the hybridoma cell line ATCC HB12346.

### Claim 16 (depends on 15)

A substantially pure population of hematopoietic progenitor cells according to claim 15, wherein said progenitor cells are obtained from human fetal liver.

### Claim 17 (depends on 15)

A substantially pure population of hematopoietic progenitor cells according to claim 15, wherein said progenitor cells are obtained from human peripheral blood.

### Claim 18 (depends on 15)

A substantially pure population of hematopoietic progenitor cells according to claim 15, wherein said progenitor cells are obtained from human bone marrow.

### Claim 19 (depends on 18)

A substantially pure population of hematopoietic progenitor cells according to claim 18, wherein said bone marrow is adult.

### Claim 20 (depends on 18)

A substantially pure population of hematopoietic progenitor cells according to claim 18, wherein said bone marrow is fetal.

### Claim 21

An isolated nucleic acid molecule, wherein said molecule comprises:
(1) a first sequence having an amino acid coding region for AC133 as set forth in FIG. 12 (SEQ ID NO:1);
(2) a second sequence, wherein said second sequence is a subsequence of said first sequence and is at least 14 nucleotides in length;
(3) a third sequence in which at least one nucleotide of said first or second sequences is replaced by a different nucleotide; or
(4) a fourth sequence complementary to any of said first, second or third sequences;
with the proviso that (i) if said molecule is an RNA molecule, U replaces T in said sequence of said molecule, (ii) said third sequence is at least 90% identical to said first or second sequence, and (iii) said second sequence is not nucleotides 347-667, 1564-1696, or 2010-2386 of SEQ ID NO:1.

### Claim 22 (depends on 21)

The isolated molecule of claim 21, wherein said molecule comprises said first sequence.

### Claim 23 (depends on 21)

The isolated molecule of claim 21, wherein said molecule comprises said second sequence.

### Claim 24 (depends on 21)

The isolated molecule of claim 21, wherein said molecule comprises said third sequence.

### Claim 25 (depends on 21)

The isolated molecule of claim 21, wherein said molecule consists essentially of DNA encoding the amino acid sequence of AC133.

### Claim 26 (depends on 21)

An expression vector comprising a nucleic acid sequence of claim 21.

### Claim 27 (depends on 26)

A cell transfected with the molecule of claim 26.

### Claim 28

An isolated polypeptide, wherein said polypeptide comprises: (1) a first amino acid sequence of AC133 as set forth in SEQ ID NO: 2; (2) a second amino acid sequence wherein said second sequence is a subsequence of said first sequences and is at least 6 amino acids in length; or (3) a third sequence in which at least one amino acid of said first or second sequences is replaced by a different amino acid, with the proviso that said amino acid replacement is a replacement of one acidic residue for another, one basic residue for another, one non-polar residue for another, one uncharged polar residue for another, or one aromatic residue for another, with the proviso that said third sequence is at least 90% identical to said first or second sequence.

### Claim 29 (depends on 28)

The isolated polypeptide of claim 28, wherein said polypeptide comprises said first sequence.

### Claim 30 (depends on 28)

The isolated polypeptide of claim 28, wherein said polypeptide comprises said second sequence.

### Claim 31 (depends on 28)

The isolated polypeptide of claim 28, wherein said polypeptide comprises said third sequence.

### Claim 32 (depends on 29)

The polypeptide of claim 29 complexed to a ligand.

### Claim 33 (depends on 32)

The polypeptide complex of claim 32, wherein said ligand is an antibody.

### Claim 34

An isolated polypeptide, wherein said polypeptide comprises the amino acid sequence from extracellular N-terminus, aa 20-107; first transmembrane region, aa 107-126; first cytoplasmic loop, aa 127-157; second transmembrane region, aa 158-179; first extracellular loop, aa 180-435; third transmembrane region, aa 436-454; second cytoplasmic loop, aa 455-480; fourth transmembrane region, aa 481-503; second extracellular loop, aa 504-792; fifth transmembrane, aa 793-816; or cytoplasmic C-terminus, aa 817-865; of SEQ ID NO:2.

### Claim 35 (depends on 8)

A method for identifying a ligand that binds to human hematopoetic stem cells, comprising detecting binding of said ligand with the polypeptide of claim 8,.

### Claim 36 (depends on 28)

A reagent that specifically binds to the polypeptide of claim 28.

### Claim 37 (depends on 36)

The reagent of claim 36, wherein said reagent is selected from the group consisting of monoclonal and polyclonal antibodies.

### Claim 38 (depends on 36)

The reagent of claim 36, wherein said reagent is a physiological or synthetic ligand.

### Claim 39 (depends on 28)

The polypeptide of claim 28, wherein said polypeptide in not glycosylated.

### Claim 40 (depends on 28)

The polypeptide of claim 28, wherein said polypeptide is glycosylated.

### Claim 41

In a method of isolating hematopoietic stem cells using a cell separation technique based on identification of stem cells by selective binding of a ligand to an antigenic marker on said stem cell, an improvement which comprises:
utilizing an AC133 antigen as said antigenic marker.

### Claim 42 (depends on 41)

The method of claim 41, wherein said ligand is an antibody.

### Claim 43 (depends on 41)

The method of claim 41, wherein said ligand binds to an extracellular region of said AC133 antigen.

### Claim 44 (depends on 41)

The method of claim 41, wherein said extracellular region comprises an amino acid selected from extracellular N-terminus, aa 20-107; first extracellular loop, aa 180-435; or second extracellular loop, aa 504-792; of SEQ ID NO:2.

### Claim 45 (depends on 41)

The method of claim 41, wherein said ligand has been identified by determining whether compounds in a group of test compounds bind to said AC133 antigen and selecting said ligand from among compounds that bind specifically to said AC133 antigen with less than 10% crossreactivity with any antigen present on mature blood cells.

### Claim 46 (depends on 41)

The method of claim 41, wherein crossreactivity is measured by a competitive binding assay between pure AC133 antigen, said ligand, and said suspected crossreactive antigen using concentrations of AC133 antigen and said ligand where said ligand half-saturates binding to AC133.

### Claim 47 (depends on 41)

The method of claim 41, wherein crossreactivity is measured at a concentration of AC133 antigen that half saturates monoclonal antibody ATCC HB 12346 when said antibody is present at a concentration of 50 ng/100 μl.

### Claim 48 (depends on 36)

A ligand for AC133 identified by the method of claim 36.

### Claim 49

A reagent that bind specifically to AC133 antigen with less than 5% crossreactivity with any antigen present on mature blood cells.

### Claim 50 (depends on 49)

The reagent of claim 49, wherein said reagent is attached to a surface or to a detectible label.

### Claim 51 (depends on 49)

The reagent of claim 49, wherein said label is a fluorescent label.
